Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer

By S. Tomlins, Daniel R. Rhodes, S. Perner, S. Dhanasekaran, R. Mehra, Xiao-wei Sun, S. Varambally, Xuhong Cao, J. Tchinda, R. Kuefer and 6 more. Science, 2005

1,824 citations recorded by the source corpus.

Subfields: Cancer Research, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/5033fa9b716c8935a919c60213db6de1a1ab1c2f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Arindam Banerjee
2. Aviv Regev
3. Christopher Sander
4. Matthew Meyerson
5. Olivier Elemento
6. Oliver Stegle
7. Chad Creighton
8. Arul M. Chinnaiyan

In Pulmonary and Respiratory Medicine

1. Arul M. Chinnaiyan
2. C. Sawyers
3. Mark A. Rubin
4. Nicolas Stransky
5. Ethan G. Cerami
6. M. Hallek

In Radiology, Nuclear Medicine and Imaging

1. Christopher Sander
2. Olivier Elemento
3. Vipin Kumar
4. Gunnar Rätsch

Citations in the corpus

• Genetics and biology of prostate cancer (2018, background): “A recurrent gene fusion of the 5′ untranslated region of TMPRSS2 to ERG (TMPRSS2:ERG) was the first translocation discovered by Chinnaiyan and colleagues (Tomlins et al. 2005).”
• Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer (2009, background): “…2007) F2 50-CGCGAGCTAAGCAGGAGGC-30 (Tu et al, 2007) R1 50-GGGGGTTGAGACAGCCAATC-30 (Rozen and Skaletsky, 2000) R2 50-GTAGGCACACTCAAACAACGACTGG-30 (Tomlins et al, 2005; Tu et al, 2007) Prostate cancer antigen 3 PCA-3 AF103907 F1 50- AGTCCGCTGTGAGTCT-30 (Rozen and Skaletsky, 2000) F2…”
• Cancer genomics: from discovery science to personalized medicine (2011, background): “and ETS transcription factor translocations in prostate cancer”
• Accuracy assessment of fusion transcript detection via read-mapping and de novo fusion transcript assembly-based methods (2019, background): “These include BCR – ABL1, found in ~ 95% of chronic myelogenous leukemia (CML) patients [3]; TMPRSS2 – ERG in ~ 50% of prostate cancers [4]; and DNAJB1 – PRKACA, the hallmark and likely driver of fibrolamellar carcinoma [5].”
• Integrative clinical genomics of advanced prostate cancer (2015, positive): “Among chimeric fusion transcripts identified, recurrent ETS fusions (Tomlins et al., 2005) were observed in 84 cases (56%), of which the majority were fused to ERG and others to FLI1, ETV4, and ETV5 (Figure 3B).”
• Integrative genomic profiling of human prostate cancer (2010, background): “Genetic Alterations Highly Associated with TMPRSS2-ERG The TMPRSS2-ERG fusion is the single most prevalent molecular lesion in prostate cancer (Tomlins et al., 2005).”
• Punctuated Evolution of Prostate Cancer Genomes (2013, neutral): “Roughly half of prostatic adenocarcinomas overexpress an oncogenic ETS transcription factor gene (most commonly ERG) because of somatic fusion with a constitutively active or androgen-regulated promoter (Tomlins et al., 2007; Tomlins et al., 2005).”
• Anomaly detection: A survey (2009, methodology): “2005], detecting anomalies in biological data [Kadota et al. 2003; Sun et al. 2006; Gwadera et al. 2005a; MacDonald and Ghosh 2007; Tomlins et al. 2005; Tibshirani and Hastie 2007], detecting anomalies in census data [Lu et al.”
• Advances in understanding cancer genomes through second-generation sequencing (2010, neutral): “Science 318, 1108–1113 (2007). 72.”